Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates (MTBVAC-03)
Phase 2a Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates Living in a High-Burden Tuberculosis-Endemic Region
Sponsor: Biofabri, S.L
Listed as NCT03536117, this PHASE2 trial focuses on Tuberculosis and remains completed. Sponsored by Biofabri, S.L, it has been updated 11 times since 2019, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
11 versions recorded-
May 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — May 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Sep 2022 — Jul 2023 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Jun 2021 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Mar 2019 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2019 — Mar 2019 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2019 — Feb 2019 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Biofabri, S.L
- South African Tuberculosis Vaccine Initiative
- TuBerculosis Vaccine Initiative
- Universidad de Zaragoza
For direct contact, visit the study record on ClinicalTrials.gov .